Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 3/20 | 0.44 |
| ▸ | SRC | P12931 | 11/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.42 |
| ▸ | YES1 | P07947 | 1/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632922 | 0.90 | JAK2 (0.48) | MAPK10SRCPDGFRBYES1EPHB4 | |
| SCHEMBL1633149 | 0.89 | CA1 (0.48) | MAPK10SRCPDGFRBYES1EPHB4 | |
| SCHEMBL1632822 | 0.86 | MAPK10 (0.49) | MAPK10SRCBRD4FGFR2JAK2 | |
| SCHEMBL1634890 | 0.86 | MAPK10 (0.47) | MAPK10BRD4FGFR2JAK2 | |
| SCHEMBL1632441 | 0.85 | MAPK10 (0.48) | MAPK10SRCPDGFRBBRD4FGFR2 | |
| SCHEMBL1633503 | 0.85 | MAPK10 (0.47) | MAPK10BRD4FGFR2ABL1JAK2 | |
| SCHEMBL1634397 | 0.85 | MAPK10 (0.59) | MAPK10SRCBRD4FGFR2JAK2 | |
| SCHEMBL1631590 | 0.84 | MAPK10 (0.50) | MAPK10FGFR2 | |
| SCHEMBL13498285 | 0.84 | MAPK10 (0.47) | MAPK10BRD4FGFR2JAK2 | |
| SCHEMBL1631671 | 0.84 | MAPK10 (0.44) | MAPK10SRCNMT1BRD4FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MAPK10 402/4885SRC 1131/4885PDGFRB 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.